VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | ECHELON-2 trial updates and the role of transplant in CD30-positive PTCL

Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some updates from the ECHELON-2 trial (NCT01777152) comparing the use of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) with standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of patients with CD30-positive peripheral T-cell lymphoma (PTCL). Dr Iyer first highlights recent updates from this trial and then goes on to discuss the value of upfront stem cell transplantation in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter